tbuckley/cabot-search huggingface dataset:
Peritraumatic Context and Long-Term Outcomes of Concussion
Authors: Emily J. Van Etten, Arielle R. Knight, Tristan A. Colaizzi, Jack Carbaugh, Alexandra Kenna, Catherine B. Fortier, William P. Milberg
Journal: JAMA Network Open (2025)

Importance There has been a great deal of interest in mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) and their association with one another, yet their interaction and subsequent associations with long-term outcomes remain poorly understood. Objective To compare the long-term outcomes of mTBI that occurred in the context of psychological trauma (peritraumatic context) with mTBI that did not (nonperitraumatic context). Design, Setting, and Participants This cohort study of post-9/11 US veterans used data from the Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) study at the Veterans Affairs Boston Healthcare System, which began in 2009; the current study utilized data from baseline TRACTS visits conducted between 2009 and 2024. Data analysis occurred from January to October 2024. Exposures Peritraumatic mTBI, nonperitraumatic mTBI, or no TBI. Main Outcomes and Measures The primary outcomes were PTSD severity (measured by the Clinician-Administered PTSD Scale–4th edition), postconcussive symptoms (measured by the Neurobehavioral Symptom Inventory), and self-reported disability status (measured by the World Health Organization Disability Assessment Schedule II). Differences between groups were compared using analyses of covariance with least significant difference comparisons. Results This sample of 567 post-9/11 veterans (mean [SD] age, 33.72 [9.29] years; 507 men [89.4%]; mean [SD] years of education, 14.19 [2.16]) included 183 individuals with no TBI, 189 individuals with nonperitraumatic mTBI, and 195 individuals with peritraumatic mTBI. Veterans with a history of peritraumatic mTBI had greater PTSD severity ( F 2,552 = 8.45; P &amp;amp;lt; .001), postconcussive symptoms ( F 2,533 = 11.09; P &amp;amp;lt; .001), and disability ( F 2,527 = 11.13; P &amp;amp;lt; .001) than the nonperitraumatic mTBI and no TBI groups. Importantly, no significant differences in any outcome measure between nonperitraumatic mTBI and no TBI groups were observed. Conclusions and Relevance This cohort study found that mTBI was only associated with long-term consequences when it co-occurred with a traumatic event exposure. This finding raises a novel hypothesis of the association of mTBI with PTSD, in which the acute biological and physiological outcomes of mTBI may be associated with temporarily scaffolding the formation of PTSD symptoms, which could enhance the production of long-term postconcussive symptoms and disability.
Facility Medicaid Payer Burden and Nonelective Admission for Chronic Limb-Threatening Ischemia
Authors: Steven Medvedovsky, Sherene E. Sharath, Panos Kougias
Journal: JAMA Surgery (2025)

Importance Chronic limb-threatening ischemia (CLTI) is a major public health issue that requires considerable human and physical resources to provide optimal patient care. It is essential to characterize the disease severity and resource needs of patients with CLTI presenting to facilities of varying resource capacities. Objective To investigate the association between facility-level Medicaid payer proportions and the incidence of nonelective admissions among patients admitted for CLTI. Design, Setting, and Participants In this retrospective multicenter cohort study, 876 026 CLTI-related inpatient admissions at 8769 US facilities from January 1, 1998, through October 31, 2020, were identified in the National Inpatient Sample. Facilities were ranked into quintiles according to increasing Medicaid burden, defined as the annualized proportion of Medicaid patient discharges for all hospitalizations. Inpatient admissions for CLTI were identified using International Classification of Diseases codes for rest pain, foot ulcers, and gangrene. Patients younger than 18 years or older than 100 years were excluded, as were those with missing admission type. Statistical analysis was conducted from January to August 2024. Exposure Facility-level Medicaid burden quintiles. Main Outcomes and Measures Emergency and urgent admissions defined as nonelective admissions. Results The study included 876 026 CLTI-related admissions (mean [SD] patient age, 68.6 [14.5] years; 54.3% men). Increasing nonelective admission rates were associated with increasing facility Medicaid burden (low Medicaid burden, 59.7%; low-moderate Medicaid burden, 62.2%; moderate Medicaid burden, 63.6%; moderate-high Medicaid burden, 63.6%; and high Medicaid burden, 66.8%; P &amp;amp;lt; .001). This trend persisted across all CLTI-related diagnoses (patients with rest pain: low Medicaid burden, 29.8%; high Medicaid burden, 36.1%; patients with lower-limb ulceration: low Medicaid burden, 63.5%; high Medicaid burden, 71.5%; and patients with gangrene: low Medicaid burden, 61.2%; high Medicaid burden, 67.4%; P &amp;amp;lt; .001). In the adjusted model, odds of nonelective admission for CLTI indications increased progressively among facilities as Medicaid burden increased from low to high (adjusted odds ratio for low-moderate Medicaid burden, 1.05 [95% CI, 1.00-1.11]; P = .06; adjusted odds ratio for high Medicaid burden, 1.44 [95% CI, 1.36-1.52]; P &amp;amp;lt; .001). Conclusions and Relevance High Medicaid burden facilities were associated with increased nonelective admissions for CLTI. This highlights an important mismatch: that resource-constrained facilities are at greater odds of seeing more resource-intensive admissions. Facility-level patient cohort characteristics should be considered when planning for resource allocation to achieve equitable patient care.
Detection of fungal pathogens by a histomolecular approach using targeted-massive parallel sequencing on formalin-fixed tissues: a retrospective study
Authors: Alexis Trecourt, Meja Rabodonirina, Marie Donzel, Bruno Simon, Claire Mauduit, Alexandra Traverse-Glehen, David Meyronet, Christophe Ginevra, Alexandra Bouyssi, Emmanuelle Chapey-Picq, Patricia Martins-Simoes, Abderrazzak Bentaher, Damien Dupont, Charline Miossec, Florence Persat, Martine Wallon, Jean-Philippe Lemoine, Pauline Tirard-Collet, Tristan Ferry, Florence Ader, Delphine Maucort-Boulch, Mojgan Devouassoux-Shisheboran, Jean Menotti
Journal: Clinical Microbiology and Infection (2025)
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia
Authors: Lukas Lauwereins, Quentin Van Thillo, Sofie Demeyer, Nicole Mentens, Sarah Provost, Kris Jacobs, Olga Gielen, Lien Boogaerts, Charles E de Bock, Guillaume Andrieu, Vahid Asnafi, Jan Cools, Alexandra Veloso
Journal: Leukemia (2025)
Validation of the Acne Core Outcomes Research Network Patient Global Assessment for Acne
Authors: Delaney Griffiths, Ali Shields, James Choe, Jerry Tan, Alison Margaret Layton, Diane Thiboutot, John S. Barbieri
Journal: JAMA Dermatology (2025)

This survey study evaluates the measurement properties for acne severity of the Acne Core Outcome Research Network (ACORN) patient global assessment.
Intranasal liposomal remdesivir induces SARS-CoV-2 clearance in K18-hACE2 mice and ensures survival
Authors: Sabrina Mendes, Lays Cordeiro Guimarães, Leonardo Camilo de Oliveira, Pedro Augusto Carvalho Costa, Natália Jordana Alves da Silva, Gabriel Silva Alves Pessim Pereira, Clara Couto Fernandez, Maria Marta Figueiredo, Robson Augusto Souza Dos Santos, Mauro Martins Teixeira, Vivian Vasconcelos Costa, Pedro Pires Goulart Guimarães, Frédéric Frézard
Journal: Journal of Controlled Release (2025)
Psychiatric, Neurological, and Somatic Comorbidities in Intermittent Explosive Disorder
Authors: Yanli Zhang-James, John Paliakkara, Joshua Schaeffer, Joseph Strayhorn, Stephen V. Faraone
Journal: JAMA Psychiatry (2025)

Intermittent explosive disorder (IED) is an understudied psychiatric condition marked by impulsive aggression and poorly regulated emotional control, often resulting in interpersonal and societal consequences. Better understanding of comorbidities can improve screening, diagnosis, and treatment. To investigate the prevalence of IED and its associations with psychiatric, neurological, and somatic disorders. In this cohort study, matched groups of patients with and without IED were identified from the TriNetX Research Network (dated January 31, 2024). Electronic medical record data were analyzed. The mean (SD) time from the first to last known visits was 4.8 (5.4) years. Lifetime diagnosis of IED. Main outcomes were International Statistical Classification of Diseases, Tenth Revision, Clinical Modification diagnostic categories and root codes. Cox proportional hazard models were used to estimate and compare probabilities of acquiring other diagnoses. Key measures include the numbers and proportions of patients with these diagnoses and adjusted hazard ratios (HRs) for IED. Overall, 30 357 individuals with IED and 30 357 demographically matched controls were included. In each group, 21 313 (70%) were male, with a mean (SD) age at the first visit 26 (17) years. Despite only 0.03% of the total patient population having an IED diagnosis, extensive comorbidities with psychiatric, neurological, and somatic conditions were found. A notable 95.7% of individuals with IED (29 054 individuals) had another psychiatric diagnosis. All psychiatric subcategories and 92% of the psychiatric diagnoses were significantly associated with IED, with HRs ranging from 2.1 (95% CI, 2.0-2.2) for substance use disorder to 76.6 (95% CI, 65.4-89.6) for disorders of adult personality and behavior (excluding IED). Among neurological conditions, neurodegenerative diseases (HR, 5.0; 95% CI, 4.1-6.1) and epilepsy (HR, 4.9; 95% CI, 4.3-5.6) had the highest HRs, followed by movement disorders (HR, 3.1; 95% CI, 2.8-3.5), cerebral palsy (HR, 2.6; 95% CI, 2.2-3.0), and sleep disorders (HR, 2.2; 95% CI, 2.1-2.3). Significant associations with IED were also observed for many somatic diseases, including obesity (HR, 1.6; 95% CI, 1.5-1.7), hyperlipidemia (HR, 1.5; 95% CI, 1.4-1.5), hypertension (HR, 1.6; 95% CI, 1.5-1.7), and gastroesophageal reflux disease (HR, 1.7; 95% CI, 1.7-1.9). These findings highlight the extensive comorbidities between IED and psychiatric, neurological, and somatic disorders, emphasizing the need for integrated diagnostic and treatment approaches addressing both psychological and physical health aspects of IED. Limitations related to reliance on medical records and low diagnostic rates of IED caution the generalizability of these findings, underscoring the need for further validation in prospective studies and more accurate, inclusive diagnosis of IED in patients with mental disorders.
Announcing “Technology and Psychiatry” and Expanding Evidence-Based Comments and Reviews in <i>JAMA Psychiatry</i>
Authors: Dost Öngür, Roy H. Perlis
Journal: JAMA Psychiatry (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Guanidyl-rich highly branched poly(β-amino ester)s for the delivery of dual CRISPR ribonucleoprotein for efficient large DNA fragment deletion
Authors: Xianqing Wang, Yinhao Li, Dana Friess, Liang Yao, Xi Wang, Zhonglei He, Wei He, Ming Li, Wenxin Wang
Journal: Journal of Controlled Release (2025)
Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo
Authors: Julien Seneschal, Mathilde Guyon, Ribal Merhi, Juliette Mazereeuw-Hautier, Nicolas Andreu, Sarah Cazenave, Khaled Ezzedine, Thierry Passeron, Katia Boniface
Journal: JAMA Dermatology (2025)

Vitiligo is a chronic autoimmune disorder leading to skin depigmentation and reduced quality of life (QOL). Patients with extensive and very active disease are the most difficult to treat. To assess the efficacy and adverse events of baricitinib combined with narrowband UV-B in adults with severe, active, nonsegmental vitiligo. This academic, multicenter, double-blind, noncomparative randomized clinical trial was conducted at 4 dermatology departments between July 2021 and April 2023 and included adult patients with extensive and active nonsegmental vitiligo. The study was designed to evaluate the effect of baricitinib plus narrowband UV-B based solely on the results from this experimental group. The placebo group was used as a calibration group. Data were analyzed from August to November 2023. Participants were randomized 3:1 to baricitinib, 4 mg per day, or placebo for 36 weeks alone for the first 12 weeks and then in combination with narrowband UV-B twice a week from weeks 12 to 36. The primary outcome was mean percentage change in total Vitiligo Area Scoring Index (VASI) score from baseline to week 36 (baricitinib group). The prespecified aim of the study was to show that the reduction in the baricitinib plus narrowband UV-B was significantly greater than 42.9%, a repigmented surface threshold previously observed in patients treated with narrowband UV-B alone. Adverse events and secondary outcomes of change in disease activity and QOL were assessed. Post hoc analyses were additionally performed. Of 49 included patients, 35 (71%) were female, and the median (IQR) age was 49.9 (38.4-59.8) years. A total of 37 patients were randomized to the baricitinib group and 12 to the placebo group. The mean change in total VASI at week 36 was -44.8% (95% CI, -58.4% to -31.3%) for the baricitinib group and -9.2% (95% CI, -27.7% to 24.7%) for the placebo group. This was not significantly greater than the sufficient repigmented surface threshold of 42.9%. Post hoc analyses showed a significant difference at week 36 for total VASI score in the baricitinib plus narrowband UV-B group compared with placebo plus narrowband UV-B (-44.8% vs -9.2%, respectively; P = .02). There was a greater improvement in disease activity and QOL in the baricitinib group vs placebo group and no significant difference in the number of adverse events. This proof-of-concept randomized clinical trial confirmed the efficacy of baricitinib combined with narrowband UV-B in the treatment of patients with extensive and active vitiligo. ClinicalTrials.gov Identifier: NCT04822584.
Fever Prevention in Acute Vascular Brain Injury—Reply
Authors: David M. Greer, Kevin N. Sheth
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
How to make remote consultations safer
Authors: Helen Saul, Samantha Cassidy, Laura Swaithes, Trisha Greenhalgh, Rebecca Payne
Journal: BMJ (2025)

The studyPayne R, Clarke A, Swann N, et al. Patient safety in remote primary care encounters: multimethod qualitative study combining Safety I and Safety II analysis. BMJ Quality and Safety 2023;0:1-14.To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/how-to-make-remote-consultations-safer/.
Exposure to Secondhand Cannabis Smoke Among Children
Authors: Osika Tripathi, Humberto Parada, Connie Sosnoff, Georg E. Matt, Penelope J. E. Quintana, Yuyan Shi, Sandy Liles, Lanqing Wang, Kevin T. Caron, James Oneill, Ben Nguyen, Benjamin C. Blount, John Bellettiere
Journal: JAMA Network Open (2025)

Importance The degree that in-home cannabis smoking can be detected in the urine of resident children is unclear. Objective Test association of in-home cannabis smoking with urinary cannabinoids in children living at home. Design, Setting, and Participants This cross-sectional study used baseline data from Project Fresh Air, a 2012-2016 randomized clinical trial to reduce fine particulate matter levels. Eligible participants were recruited from households in San Diego County, California, with children under age 14 years and an adult tobacco smoker in residence. Children’s urine samples were analyzed in 2022. Exposures In-home cannabis smoking, measured by: parent or guardian report of in-home cannabis smoking; number of daily nonspecific smoking events computed via an air particle count algorithm; and number of daily cannabis smoking events ascertained by residualization, adjusting for air nicotine, tobacco smoking, and other air particle generating or ventilating activities. Main Outcomes and Measures Levels of the cannabis biomarker Δ 9 -tetrahydrocannabinol (THC) and its major metabolites, 11-hydroxy-Δ 9 -tetrahydrocannabinol and 11-nor-9-carboxy-Δ 9 -tetrahydrocannabinol. Biomarker molar equivalents were summed to represent total THC equivalents (TTE) in urine. Logistic regression assessed whether in-home smoking was associated with cannabis biomarker detection. For children with detectable urinary cannabinoids, linear regression assessed in-home smoking association with quantity of urinary TTE. Results A total of 275 children were included in analysis (mean [SD] age, 3.6 [3.6] years; 144 male [52.4%]; 38 Black [13.8%], 132 Hispanic [48.0%], and 52 White [18.9%]). Twenty-nine households (10.6%) reported in-home cannabis smoking in the past 7 days; 75 children [27.3%] had detectable urinary cannabinoids. Odds of detectable TTE in children’s urine were significantly higher in households with reported in-home cannabis smoking than households without (odds ratio [OR], 5.0; 95% CI, 2.4-10.4) and with each additional ascertained daily cannabis smoking event (OR, 2.5; 95% CI, 1.6-3.9). Although the point estimate for TTE levels was higher among children with detectable urinary cannabinoids and exposure to more daily cannabis smoking events (increase per event, 35.68%; 95% CI, −7.12% to 98.21%), the difference was not statistically significant. Conclusions and Relevance In this cross-sectional study, in-home cannabis smoking was associated with significantly increased odds of child exposure to cannabis smoke, as assessed by urinary cannabinoid biomarkers. As young children spend most of their time at home, reducing in-home cannabis smoking could substantially reduce their exposure to the toxic and carcinogenic chemicals found in cannabis smoke.
Blood Biomarkers to Detect Alzheimer Disease
Authors: Yishai Mintzker
Journal: JAMA (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal